aTyr Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, aTyr Pharma sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
aTyr Pharma: 9 sponsored US clinical trials, 1 recruiting.
aTyr Pharma sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Facioscapulohumeral Muscular Dystrophy (FSHD), with 1 trials.
Top-decile sponsor footprint
aTyr Pharma ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
NCT05892614
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
NCT05415137
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
NCT04412668
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
NCT03824392
Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT02836418
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
NCT02603562
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT02579239
Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension
NCT02531217
Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy
NCT02239224
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the aTyr Pharma pipeline
1 recruiting of 9 indexed (11% open); 7 completed (78%).
Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Facioscapulohumeral Muscular Dystrophy (FSHD) (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
aTyr Pharma: open-pipeline peers nationwide
Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
aTyr Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
Related
What to do with this aTyr Pharma page
9 registered trials is a research-attention snapshot, not an endorsement of aTyr Pharma or any single study.
- 1 of aTyr Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Facioscapulohumeral Muscular Dystrophy (FSHD) is the condition aTyr Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Facioscapulohumeral Muscular Dystrophy (FSHD) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. aTyr Pharma pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.